Community

Thursday, 15 December 2016

Drug company’s new R&D facility set to become operational

Hovid’s bio-equivalence centre in Bayan Lepas, Penang, is expected to be up and running next year.

Hovid’s bio-equivalence centre in Bayan Lepas, Penang, is expected to be up and running next year.

HOVID Bhd has set up a bio-equivalence (BE) studies centre at Bayan Lepas, Penang to enhance its pharmaceutical research and development.

A spokesman from Hovid said the RM15mil centre has already been built and is in the process of getting a licence from the National Pharmaceutical Control Bureau.

“We are hoping the get the licence by next year.

“The centre will conduct bio-equivalence studies to compare and analyse medicinal products that contains the same active substance,” the spokesperson said.

“There will also be about 48 beds for the volunteers in the BE tests to stay overnight,” she said.

“The centre will also develop all generic products including cardiovascular and diabetic range,” she added.

The spokesperson also said Hovid will be expanding its Chemor manufacturing plant next year.

She said the expansion project will cost some RM42mil and will see the usage of automation and to increase the quantity and quality in production.

“The expanded plant will be able to produce more than 100 different tablets and capsules for various conditions, including anti-diabetic, anti-hypertension, antibiotics, pain management and others.

“The expansion will be split into two phase, with the objective to grow tablet and capsule production for the next three to five years,” she said, adding that the expansion is expected to be in operation in the first half of next year.

“To keep up with the expansion, Hovid will also use a centralised and automated system at its warehouse for better inventory control and shipment of more than 400 products to 50 countries worldwide,” she added.

Tags / Keywords: Perak , Family Community , research , pharmaceutical

advertisement

Powered by

advertisement

advertisement